UPCC 45418: An Open-Label Phase I/II Safety and Efficacy Study of Itacitinib in Combination with Everolimus in Subjects with Relapsed/Refractory Classical Hodgkin Lymphoma
Enrolling By Invitation
99 years or below
All
Phase
2
23 participants needed
1 Location
Brief description of study
The study will assess how safe and well-tolerated a combination of the study drugs itacitinib and everolimus in patients with Hodgkin lymphoma. We also hope to learn how effective this experimental combination is in treating Hodgkin lymphoma, when given together.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: lymphoma
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 831774
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
